JNK/SAPK mediates doxorubicin-induced differentiation and apoptosis in MCF-7 breast cancer cells

Breast Cancer Research and Treatment

Volumn 79, Issue 3, 2003, Pages 321-328

  Kim, Jayoung ^a,b   Freeman, Michael R ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Breast cancer; Differentiation; Doxorubicin; JNK SAPK

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANSAMYCIN DERIVATIVE; ANTHRACYCLINE ANTIBIOTIC AGENT; BIOLOGICAL MARKER; CYTOKERATIN 18; CYTOKERATIN 8; DOXORUBICIN; MEMBRANE PROTEIN; NOCODAZOLE; QUINIDINE; STRESS ACTIVATED PROTEIN KINASE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL DIFFERENTIATION; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL DIFFERENTIATION; DNA, NEOPLASM; DOXORUBICIN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

EID: 0038575868     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024043302583     Document Type: Article

References (43)

1. Chew HK: Medical management of breast cancer: today and tomorrow. Cancer Biother Radio 17: 137-149, 2002
2. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics, 2000. CA-Cancer J Clin 50: 7-33, 2000
3. Guano F, Pourquier P, Tinelli S, Binaschi M, Bigioni M, Animati F, Manzini S, Zunino F, Kohlhagen G, Pommier Y, Capranico G: Topoisomerase poisoning activity of novel disaccharide anthracyclines. Mol Pharmacol 56: 77-84, 1999
4. Muller I, Niethammer D, Bruchelt G: Anthracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity (Review). Int J Mol Med 1: 491-494, 1998
5. Gamen S, Anel A, Perez-Galan P, Lasierra P, Johnson D, Pineiro A, Naval J: Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res 258: 223-235, 2000
6. Hayakawa K, Hasegawa M, Kawashima M, Nakamura Y, Matsuura M, Toda H, Mitsuhashi N, Niibe H: Comparison of effects of doxorubicin and radiation on p53-dependent apoptosis in vivo. Oncol Rep 7: 267-270, 2000
7. Lu Y, Tatsuka M, Takebe H, Yagi T: Involvement of cyclin-dependent kinases in doxorubicin-induced apoptosis in human tumor cells. Mol Carcinogen 29: 1-7, 2000
8. Skladanowski A, Konopa J: Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumour cells. Biochem Pharmacol 46: 375-382, 1993
9. Cece R, Cazzaniga S, Morelli D, Sfondrini L, Bignotto M, Menard S, Colnaghi MI, Balsari A: Apoptosis of hair follicle cells during doxorubicin-induced alopecia in rats. Lab Invest 75: 601-609, 1996
10. Jing Y, Zhang J, Waxman S, Mira-y-Lopez R: Upregulation of cytokeratins 8 and 18 in human breast cancer T47D cells is retinoid-specific and retinoic acid receptor-dependent. Differentiation 60: 109-117, 1996
11. Kang YJ, Chen Y, Yu A, Voss-McCowan M, Epstein PN: Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 100: 1501-1506, 1997
12. Kang YJ, Li G, Saari JT: Metallothionein inhibits ischemia-reperfusion injury in mouse heart. Am J Physiol 276: H993-H997, 1999
13. Kogawa K, Muramatsu H, Tanaka M, Nishihori Y, Hagiwara S, Kuribayashi K, Nakamura K, Koike K, Sakamaki S, Niitsu Y: Enhanced inhibition of experimental metastasis by the combination chemotherapy of Cu-Zn SOD and adriamycin. Clin Exp Metastas 17: 239-244, 1999
14. Sartorelli AC: The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach. Brit J Cancer 52: 293-302, 1985
15. Scott RE: Differentiation, differentiation/gene therapy and cancer. Pharmacol Therapeut 73: 51-65, 1997
16. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB: Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Therapeut 90: 105-156, 2001
17. Guilbaud NF, Gas N, Dupont MA, Valette A: Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J Cell Physiol 145: 162-172, 1990
18. Bacus SS, Kiguchi K, Chin D, King CR, Huberman E: Differentiation of cultured human breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen. Mol Carcinogen 3: 350-362, 1990
19. Fornari Jr FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FK, Mumaw VR, Lovings ET, Freeman RH, Gewirtz DA: Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ 5: 723-733, 1994
20. Constantinou AI, Krygier AE, Mehta RR: Genistein induces maturation of cultured human breast cancer cells and prevents tumor growth in nude mice. Am J Clin Nutr 68: 1426S-1430S, 1998
21. Bani D, Flagiello D, Poupon MF, Nistri S, Poirson-Bichat F, Bigazzi M, Bani Sacchi T: Relaxin promotes differentiation of human breast cancer cells MCF-7 transplanted into nude mice. Virchows Arch 435: 509-519, 1999
22. Agarwal C, Sharma Y, Zhao J, Agarwal R: A polyphenolic fraction from grape seeds causes irreversible growth inhibition of breast carcinoma MDA-MB468 cells by inhibiting mitogen-activated protein kinases activation and inducing G1 arrest and differentiation. Clin Cancer Res 6: 2921-2930, 2000
23. Zhou Q, Melkoumian ZK, Lucktong A, Moniwa M, Davie JR, Strobl JS: Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. J Biol Chem 275: 35256-35263, 2000
24. Li C, Ahlborn TE, Kraemer FB, Liu J: Oncostatin M-induced growth inhibition and morphological changes of MDA-MB231 breast cancer cells are abolished by blocking the MEK/ERK signaling pathway. Breast Cancer Res Tr 66: 111-121, 2001
25. Munster PN, Srethapakdi M, Moasser MM, Rosen N: Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 61: 2945-2952, 2001
26. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM: The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61: 8492-8497, 2001
27. You H, Yu W, Sanders BG, Kline K: RRR-alpha-tocopheryl succinate induces MDA-MB-435 and MCF-7 human breast cancer cells to undergo differentiation. Cell Growth Differ 12: 471-480, 2001
28. Han J, Wang X, Jiang Y, Ulevitch RJ, Lin S: Identification and characterization of a predominant isoform of human MKK3. FEBS Lett 403: 19-22, 1997
29. Westermarck J, Li SP, Kallunki T, Han J, Kahari VM: p38 mitogen-activated protein kinase-dependent activation of protein phosphatases 1 and 2A inhibits MEK1 and MEK2 activity and collagenase 1 (MMP-1) gene expression. Mol Cell Biol 21: 2373-2383, 2001
30. Kim J, Adam RM, Freeman MR: Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 62: 1549-1554, 2002
31. Chen YR, Wang X, Templeton D, Davis RJ, Tan TH: The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 271: 31929-31936, 1996
32. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995
33. Lin J, Adam RM, Santiestevan E, Freeman MR: The phosphatidylinositol 3′-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res 59: 2891-2897, 1999
34. Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel E: Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 2: 1879-1885, 1996
35. Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB, Ullrich A, Sela M, Yarden Y: Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res 52: 2580-2589, 1992
36. Kiguchi K, Giometti C, Chubb CH, Fujiki H, Huberman E: Differentiation induction in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A. Biochem Bioph Res Co 189: 1261-1267, 1992
37. Weston CR, Davis RJ: The JNK signal transduction pathway. Curr Opin Genet Dev 12: 14-21, 2002
38. Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR, Kufe DW: Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 376: 785-788, 1995
39. Kharbanda S, Pandey P, Ren R, Mayer B, Zon L, Kufe D: c-Abl activation regulates induction of the SEK1/stress-activated protein kinase pathway in the cellular response to 1-beta-D-arabinofuranosylcytosine. J Biol Chem 270: 30278-30281, 1995
40. Davis RJ: Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252, 2000
41. Fan M, Chambers TC: Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Update 4: 253-267, 2001
42. Wang H, Ikeda S, Kanno S, Guang LM, Ohnishi M, Sasaki M, Kobayashi T, Tamura S: Activation of c-Jun amino-terminal kinase is required for retinoic acid-induced neural differentiation of P19 embryonal carcinoma cells. FEBS Lett 503: 91-96, 2001
43. Ding Q, Wang Q, Evers BM: Alterations of MAPK activities associated with intestinal cell differentiation. Biochem Bioph Res Co 284: 282-288, 2001